The Guardian of the Genome Revisited: p53 Downregulates Genes Required for Telomere Maintenance, DNA Repair, and Centromere Structure
暂无分享,去创建一个
[1] D. M. Martin,et al. Inappropriate p53 Activation During Development Induces Features of CHARGE Syndrome , 2014, Nature.
[2] L. Attardi,et al. p53 at a glance , 2010, Journal of Cell Science.
[3] B. Vogelstein,et al. Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.
[4] P. Fei,et al. Fanconi Anemia Signaling and Cancer. , 2017, Trends in cancer.
[5] W. Fok,et al. p53 Mediates Failure of Human Definitive Hematopoiesis in Dyskeratosis Congenita , 2017, Stem cell reports.
[6] Stephen J Chanock,et al. Genetic variation, nucleotide diversity, and linkage disequilibrium in seven telomere stability genes suggest that these genes may be under constraint , 2005, Human mutation.
[7] S. Volarevic,et al. Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis. , 2014, Biochimica et biophysica acta.
[8] M. Kaufman,et al. High-frequency developmental abnormalities in p53-deficient mice , 1995, Current Biology.
[9] Stephen N. Jones,et al. p53 mutant mice that display early ageing-associated phenotypes , 2002, Nature.
[10] V. Rotter,et al. A DNA binding domain is contained in the C-terminus of wild type p53 protein. , 1991, Nucleic acids research.
[11] Kevin M. Ryan,et al. p53 and metabolism , 2009, Nature Reviews Cancer.
[12] P. Shaw,et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[13] F. Toledo,et al. Cancer: Three birds with one stone , 2009, Nature.
[14] D. Hanahan,et al. Mouse models for the study of telomerase. , 1997, Ciba Foundation symposium.
[15] Manuel Serrano,et al. The Hallmarks of Aging , 2013, Cell.
[16] J. Bodalski,et al. FANCONI'S ANAEMIA AND DYSKERATOSIS CONGENITA AS A SYNDROME. , 1963, Dermatologica.
[17] F. Gage,et al. Puma is required for p53-induced depletion of adult stem cells , 2010, Nature Cell Biology.
[18] Xiaodong Qi,et al. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. , 2011, Blood.
[19] S. Savage,et al. The genomics of inherited bone marrow failure: from mechanism to the clinic , 2017, British journal of haematology.
[20] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[21] P. Cahan,et al. Poly(A)-specific ribonuclease (PARN) mediates 3′-end maturation of the telomerase RNA component , 2015, Nature Genetics.
[22] H. Kiyokawa,et al. Tumor-prone phenotype of the DDB2-deficient mice , 2005, Oncogene.
[23] Eléonore Toufektchan,et al. p53 downregulates the Fanconi anaemia DNA repair pathway , 2016, Nature Communications.
[24] C. Harris,et al. Clinical outcomes and correlates of TP53 mutations and cancer. , 2010, Cold Spring Harbor perspectives in biology.
[25] B. Liu,et al. ROS and p53: a versatile partnership. , 2008, Free radical biology & medicine.
[26] J. Espinosa,et al. Mechanisms of transcriptional regulation by p53 , 2017, Cell Death and Differentiation.
[27] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[28] R. Bernards,et al. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence , 2006, Nature Cell Biology.
[29] Yie Liu,et al. Fanconi anemia proteins in telomere maintenance. , 2016, DNA repair.
[30] K. Engeland,et al. p53 can repress transcription of cell cycle genes through a p21WAF1/CIP1-dependent switch from MMB to DREAM protein complex binding at CHR promoter elements , 2012, Cell cycle.
[31] Valerie Reinke,et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 , 2001, Nature Genetics.
[32] R. DePinho,et al. Telomeres and telomerase in cancer. , 2010, Carcinogenesis.
[33] G. Wahl,et al. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.
[34] K. Offit,et al. A Recessive Founder Mutation in Regulator of Telomere Elongation Helicase 1, RTEL1, Underlies Severe Immunodeficiency and Features of Hoyeraal Hreidarsson Syndrome , 2013, PLoS genetics.
[35] M. Fischer,et al. The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes , 2015, Nucleic acids research.
[36] B. Honig,et al. Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode , 2016, Nature.
[37] Lawrence A. Donehower,et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.
[38] G. Lozano. Mouse models of p53 functions. , 2010, Cold Spring Harbor perspectives in biology.
[39] L. Attardi,et al. Deciphering p53 signaling in tumor suppression. , 2018, Current opinion in cell biology.
[40] S. Lowe. Activation of p53 by oncogenes. , 1999, Endocrine-related cancer.
[41] V. Rotter. p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[42] L. Donehower,et al. Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity , 2007, Mechanisms of Ageing and Development.
[43] P. Chumakov,et al. The antioxidant function of the p53 tumor suppressor , 2005, Nature Medicine.
[44] Q. Zhan. Gadd45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA damage. , 2005, Mutation research.
[45] G. Almouzni,et al. Essential role for centromeric factors following p53 loss and oncogenic transformation , 2017, Genes & development.
[46] D. Lane,et al. T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.
[47] M. E. Perry,et al. mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation , 2003, Molecular and Cellular Biology.
[48] H. Walden,et al. The Fanconi anemia DNA repair pathway: structural and functional insights into a complex disorder. , 2014, Annual review of biophysics.
[49] Vanesa Gottifredi,et al. p53 Down-Regulates CHK1 through p21 and the Retinoblastoma Protein , 2001, Molecular and Cellular Biology.
[50] G. Wahl,et al. Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. , 2011, Genes & development.
[51] I. Demuth,et al. SNM1B/Apollo in the DNA damage response and telomere maintenance , 2017, Oncotarget.
[52] P. Cahan,et al. Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease. , 2016, The Journal of clinical investigation.
[53] K. Engeland,et al. Timing of transcription during the cell cycle: Protein complexes binding to E2F, E2F/CLE, CDE/CHR, or CHR promoter elements define early and late cell cycle gene expression , 2016, Oncotarget.
[54] A. Levine,et al. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.
[55] M. Oren,et al. The loss of mdm2 induces p53 mediated apoptosis , 2000, Oncogene.
[56] J. Manfredi,et al. The Tail That Wags the Dog: How the Disordered C-Terminal Domain Controls the Transcriptional Activities of the p53 Tumor-Suppressor Protein. , 2016, Trends in biochemical sciences.
[57] M. Oren,et al. p53 and ribosome biogenesis stress: The essentials , 2014, FEBS letters.
[58] Transcriptional repression of DNA repair genes is a hallmark and a cause of cellular senescence , 2018, Cell Death & Disease.
[59] A. Bertuch. The molecular genetics of the telomere biology disorders , 2016, RNA biology.
[60] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[61] E. Appella,et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[62] G. Lozano,et al. The p53–Mdm2 network in progenitor cell expansion during mouse postnatal development , 2007, The Journal of pathology.
[63] M. Kastan. Commentary on "Participation of p53 Protein in the Cellular Response to DNA Damage". , 2016, Cancer research.
[64] Sathish Kumar Mungamuri,et al. p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes , 2013, Oncogene.
[65] D. Broccoli,et al. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. , 1999, Science.
[66] K. Helin,et al. Mdm4 (Mdmx) Regulates p53-Induced Growth Arrest and Neuronal Cell Death during Early Embryonic Mouse Development , 2002, Molecular and Cellular Biology.
[67] G. Wahl,et al. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[68] J. Bourdon,et al. Mutant mice lacking the p53 C-terminal domain model telomere syndromes. , 2013, Cell reports.
[69] J. Soulier,et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. , 2012, Cell stem cell.
[70] María A Blasco,et al. Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA , 1997, Cell.
[71] C. Prives,et al. Relevance of the p53–MDM2 axis to aging , 2017, Cell Death and Differentiation.
[72] D. Lane,et al. p53, guardian of the genome , 1992, Nature.
[73] P. Saetrom,et al. Cell cycle regulation of human DNA repair and chromatin remodeling genes. , 2015, DNA repair.
[74] G. Lozano,et al. Haploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development , 2007, Molecular and Cellular Biology.
[75] V. J. Selmanowitz,et al. Dyskeratosis congenita: relationship to Fanconi's anemia. , 1972, Blood.
[76] W. Maltzman,et al. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.
[77] D. Lane,et al. Cancer. p53, guardian of the genome. , 1992, Nature.
[78] K. Mohammad,et al. Modulation of mammalian life span by the short isoform of p53. , 2004, Genes & development.
[79] R. Yerushalmi,et al. BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities in vitro and in vivo , 2015, Oncotarget.
[80] K. Engeland. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM , 2017, Cell Death and Differentiation.
[81] P. May,et al. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum , 1979, Journal of virology.
[82] V. Plagnol,et al. Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita. , 2015, The Journal of clinical investigation.
[83] C. Schildkraut,et al. FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres , 2017, Proceedings of the National Academy of Sciences.
[84] B. Alter,et al. VACTERL-H Association and Fanconi Anemia , 2012, Molecular Syndromology.
[85] Sathish Kumar Mungamuri,et al. The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo , 2013, Genes & development.
[86] Guillermina Lozano,et al. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.
[87] Magali Olivier,et al. TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.
[88] R. Tothill,et al. Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors , 2008, Molecular Cancer Research.
[89] Matthias Dobbelstein,et al. p21/CDKN1A Mediates Negative Regulation of Transcription by p53* , 2003, Journal of Biological Chemistry.
[90] G. Joksiċ,et al. Dysfunctional telomeres in primary cells from Fanconi anemia FANCD2 patients , 2012, Genome Integrity.
[91] Paul G. Gauger,et al. Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling , 2009, Clinical Cancer Research.
[92] P. Sung,et al. Stress and DNA repair biology of the Fanconi anemia pathway. , 2014, Blood.
[93] M. R. Murphy,et al. PARN deadenylase is involved in miRNA-dependent degradation of TP53 mRNA in mammalian cells , 2015, Nucleic acids research.
[94] F. Toledo,et al. Ribosome biogenesis dysfunction leads to p53-mediated apoptosis and goblet cell differentiation of mouse intestinal stem/progenitor cells , 2015, Cell Death and Differentiation.
[95] Eduardo Sontag,et al. Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.
[96] L. Attardi,et al. Unravelling mechanisms of p53-mediated tumour suppression , 2014, Nature Reviews Cancer.
[97] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[98] Christopher Y. Park,et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects , 2008, Nature Genetics.
[99] C. Prives,et al. Dysfunction of the MDM2/p53 axis is linked to premature aging. , 2017, The Journal of clinical investigation.
[100] V. Mazzaferro,et al. Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma , 2007, Hepatology.
[101] B. Tian,et al. Positive and negative feedback loops in the p53 and mRNA 3′ processing pathways , 2013, Proceedings of the National Academy of Sciences.
[102] J. Benítez,et al. BRCA2 Acts as RAD51 Loader to Facilitate Telomere Replication and Capping , 2010, Nature Structural &Molecular Biology.
[103] Yiming Zhu,et al. A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models , 2018, eLife.
[104] S. Jaber,et al. Les liaisons dangereuses : p53, dyskératose congénitale et anémie de Fanconi , 2017 .
[105] Richard C. Wang,et al. Engineered telomere degradation models dyskeratosis congenita. , 2008, Genes & development.
[106] L. Donehower. Using mice to examine p53 functions in cancer, aging, and longevity. , 2009, Cold Spring Harbor perspectives in biology.
[107] Björn Schumacher,et al. p53 in the DNA-Damage-Repair Process. , 2016, Cold Spring Harbor perspectives in medicine.
[108] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[109] S. Benchimol,et al. From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: The telomere loss/DNA damage model of cell aging , 1996, Experimental Gerontology.
[110] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.